News | September 20, 2013

Fully Dissolvable Coronary Stent Being Tested at Mount Sinai Medical Center

abbott vascular, abbott laboratories, abbott bioresorbable stents

Abbott Bioresorbable Vascular Scaffold

September 20, 2013— The Mount Sinai Medical Center is participating in the nationwide Absorb III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting stent to open heart artery blockages. The randomized trial aims to compare the efficiency and safety of Absorb Bioresorbable Vascular Scaffolds (Absorb BVS) in coronary artery disease patients and compare it to the current standard of care — drug eluting metal stents.

Absorb BVS is a flexible artery support tube made of a naturally dissolvable material called polylactide. It is inserted by interventional cardiologists with minimal invasiveness during a cardiac catheterization procedure. Absorb BVS works to line the interior of a blocked heart artery to keep it open and restore proper blood flow to the heart. The supportive tube then dissolves into the artery wall within two years.

Dissolvable stents may be a future game-changer for the way we treat coronary artery disease and heart attack in the United States if proven to show clinical benefit in this nationwide clinical trial,” says Samin K. Sharma, M.D., director of Clinical and Interventional Cardiology at The Mount Sinai Medical Center and the Zena and Michael A. Wiener professor of medicine at Icahn School of Medicine at Mount Sinai. “The stent is designed to open a blocked heart vessel and eventually dissolve and disappear, leaving no remnants on the heart of a cardiac interventional procedure.”

“Heart disease is still the number one killer of Americans. This is why we need to study in clinical trial every available therapeutic option for our heart patients to improve their overall heart health and prevent future deadly heart attacks,” says Roxana Mehran, M.D., director of Interventional Cardiovascular Research and Clinical Trials at Icahn School of Medicine. “It is critical that advances in cardiac interventional technology, currently being used on other continents to help unblock arteries, be tested in clinical trial in the United States.”

The randomized Absorb III clinical trial plans to enroll approximately 2,250 coronary artery disease patients across the country. Mount Sinai hopes to enroll 50 patients.

Recently, Absorb BVS became commercially available in Europe, India, and parts of Latin America and Asia. So far, more than 1,000 patients around the world have been treated with the device. Absorb BVS is made by the global healthcare company Abbott.

Mount Sinai study co-investigators Sharma and Pedro Moreno, M.D., receive financial compensation as lecturers for Abbott Laboratories, the study’s sponsor and manufacturer of Absorb BVS. Also, as a consultant for Abbott, Mehran receives financial compensation.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init